understand
tempor
dynam
patient
phenotyp
necessari
deriv
finegrain
resolut
pathophysiolog
use
stateoftheart
deep
neural
network
institutionwid
machin
intellig
platform
augment
curat
million
clinic
note
patient
subject
pcr
diagnost
test
contrast
electron
health
record
ehr
deriv
clinic
phenotyp
covidpo
versu
covidneg
patient
day
week
preced
pcr
test
date
identifi
diarrhea
chang
appetit
anosmiadysgeusia
respiratori
failur
significantli
amplifi
covidpo
covidneg
patient
specif
combin
cough
diarrhea
amplif
covidpo
patient
week
prior
pcr
test
along
anosmiadysgeusia
constitut
earliest
ehrderiv
signatur
day
prior
typic
pcr
test
date
studi
introduc
augment
intellig
platform
realtim
synthesi
institut
knowledg
captur
ehr
platform
hold
tremend
potenti
scale
curat
throughput
minim
need
train
underli
neural
network
thu
promis
ehrpow
earli
diagnosi
broad
spectrum
diseas
introduc
platform
augment
curat
fullspectrum
patient
phenotyp
clinic
note
mayo
clinic
ehr
patient
confirm
positiveneg
diagnosi
pcr
test
see
method
platform
util
stateoftheart
transform
neural
network
unstructur
clinic
note
autom
entiti
recognit
eg
diseas
drug
phenotyp
quantifi
strength
contextu
associ
entiti
character
natur
associ
posit
neg
sentiment
identifi
specif
gastrointestin
respiratori
sensori
phenotyp
well
specif
combin
appear
indic
impend
covidpo
diagnosi
pcr
test
highlight
potenti
neural
networkspow
ehr
curat
facilit
significantli
earlier
diagnosi
current
thought
feasibl
clinic
determin
statu
patient
conduct
use
pcr
rna
test
approv
human
nasopharyng
oropharyng
swab
specimen
us
fda
emerg
use
author
eua
pcr
test
result
covidneg
patient
diagnos
covidpo
patient
diagnos
order
investig
time
cours
progress
patient
use
bertbas
deep
neural
network
extract
symptom
put
synonym
clinic
note
week
prior
week
post
date
diagnosi
test
taken
see
method
tabl
purpos
analysi
patient
tempor
align
set
date
pcr
test
day
proport
patient
demonstr
symptom
deriv
ehr
day
week
preced
post
pcr
test
tabul
tabl
neg
control
includ
symptom
dysuria
covidpo
patient
diarrhea
occur
patient
week
prior
pcr
test
date
wherea
covidneg
patient
patient
confirm
diarrhea
week
prior
pcr
test
date
amplifi
probabl
tabl
pvalu
diarrhea
week
preced
pcr
test
covidpo
patient
quit
noteworthi
undiagnos
patient
experi
diarrhea
may
unintent
shed
fecal
incident
epidemiolog
surveil
wast
water
monitor
conduct
recent
state
massachusett
observ
copiou
rna
amplif
diarrhea
covidpo
covidneg
patient
week
preced
pcr
test
highlight
import
necess
wash
hand
often
chang
appetiteintak
amplifi
week
preced
pcr
test
covidpo
covidneg
patient
tabl
amplif
pvalu
alter
diminish
sens
tast
smell
dysgeusia
anosmia
significantli
amplifi
covidpo
covidneg
patient
week
preced
pcr
test
tabl
amplif
pvalu
result
suggest
anosmia
like
signific
earli
indic
includ
otherwis
asymptomat
patient
respiratori
failur
modestli
enrich
week
prior
pcr
test
covidpo
covidneg
patient
amplif
pvalu
tabl
among
common
phenotyp
diaphoresi
manifest
patient
fatigu
patient
week
prior
covidpo
pcr
test
contrast
covidneg
patient
diaphoresi
occur
patient
fatigu
week
prior
pcr
test
correspond
amplif
diaphoresi
pvalu
amplif
fatigu
pvalu
headach
occur
covidpo
patient
covidneg
patient
reflect
amplif
covidpo
patient
week
prior
pcr
test
pvalu
cough
amplif
pvalu
covidpo
covidneg
patient
week
preced
pcr
test
tabl
feverchil
occur
covidpo
patient
covidneg
patient
week
prior
pcr
test
suggest
feverchil
somewhat
nonspecif
patient
final
dysuria
includ
neg
control
consist
assumpt
covidpo
patient
covidneg
patient
dysuria
week
preced
pcr
test
tabl
next
consid
possibl
pairwis
conjunct
phenotyp
covidpo
versu
covidneg
patient
week
prior
pcr
test
date
tabl
given
alter
sens
smell
tast
anosmiadysgeusia
occur
conjunct
within
covidpo
patient
till
date
fact
independ
anosmiadysgeusia
alreadi
signific
signatur
impend
covidpo
diagnosi
base
result
remark
possibl
pairwis
symptom
combin
combin
cough
diarrhea
note
particularli
signific
covidpo
covidneg
patient
week
preced
pcr
test
ie
cough
diarrhea
cooccur
covidpo
patient
covidneg
patient
indic
amplif
specif
symptom
combin
signatur
impend
diagnosi
bh
correct
pvalu
anoth
enrich
combin
symptom
covidpo
covidneg
patient
week
preced
pcr
test
diaphoresi
diarrhea
cooccur
covidpo
covidneg
patient
correspond
enrich
bh
correct
pvalu
covidpo
patient
group
suggest
diaphoresi
diarrhea
anoth
symptom
combin
preced
covidpo
pcr
test
result
investig
tempor
evolut
proport
patient
symptom
week
prior
pcr
test
cough
diarrhea
found
earli
indic
significantli
discrimin
covidpo
covidneg
patient
particular
day
prior
pcr
test
cough
amplifi
covidpo
patient
cohort
covidneg
patient
cohort
amplif
day
pvalu
day
pvalu
day
pvalu
day
pvalu
day
pvalu
intrigu
diminish
odd
cough
symptom
day
preced
pcr
test
date
suggest
may
notabl
tempor
pattern
likewis
diarrhea
amplifi
covidpo
patient
cohort
covidneg
patient
cohort
amplif
day
pvalu
day
pvalu
day
pvalu
day
pvalu
follow
enrich
odd
diarrhea
cough
find
chang
appetit
may
consid
subsequ
symptom
impend
diagnosi
chang
appetit
amplifi
covidpo
cohort
covidneg
cohort
day
pvalu
day
pvalu
day
pvalu
final
day
pcr
test
ensu
feverchil
enrich
covidpo
covidneg
cohort
day
pvalu
day
pvalu
day
pvalu
respect
similarli
cough
also
amplifi
covidpo
covidneg
cohort
day
pvalu
day
pvalu
day
pvalu
post
pcr
test
date
observ
character
tempor
evolut
specif
phenotyp
enrich
covidpo
patient
preced
post
pcr
test
date
explicit
identif
patient
prior
pcr
test
date
conduct
prospect
valid
augment
ehr
curat
approach
initi
nevertheless
highresolut
tempor
overview
ehrderiv
clinic
phenotyp
relat
pcr
diagnost
test
date
patient
reveal
specif
enrich
signal
impend
onset
clinic
insight
help
modul
social
distanc
measur
appropri
clinic
care
individu
exhibit
specif
gastrointestin
diarrhea
chang
appetiteintak
sensori
anosmia
dysgeusia
respiratori
phenotyp
identifi
herewith
includ
patient
await
conclus
diagnost
test
result
eg
rna
rtpcr
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
order
identifi
potenti
cell
tissu
type
may
associ
ehrderiv
clinic
phenotyp
observ
patient
analyz
singl
cell
rnaseq
data
use
nferx
platform
see
method
given
recent
studi
implic
necess
lifecycl
scout
human
cell
coexpress
gene
coexpress
analysi
reveal
specif
cell
type
small
intestinecolon
nasal
caviti
respiratori
system
pancrea
urinari
tract
gallbladd
coexpress
figur
figur
notabl
multipl
small
intestin
cell
type
coexpress
two
gene
cell
type
includ
enterocyt
enteroendocrin
cell
stem
cell
goblet
cell
paneth
cell
pancrea
cell
type
includ
ductal
cell
acinar
cell
kidney
cell
coexpress
includ
proxim
tubular
cell
pelvic
epitheli
cell
type
intercal
cell
coexpress
also
observ
epitheli
cell
olfactori
nasal
caviti
respiratori
tract
well
type
ii
pneumocyt
albeit
compar
lower
level
identifi
tissu
show
coexpress
gastrointestin
respiratori
sensori
system
correl
clinic
phenotyp
earli
infect
describ
insight
conceiv
normalhealthi
tissu
highlight
need
meticul
biobank
patientderiv
biospecimen
character
via
singl
cell
rnaseq
molecular
technolog
primari
prevent
effect
method
minim
spread
contagi
infecti
virus
figur
addit
populationbas
strategi
social
distanc
signific
ongo
effort
develop
prophylact
solut
tabl
immunodomin
humor
immun
respons
patient
direct
spike
protein
mani
vaccin
investig
target
viral
protein
remain
determin
whether
antispik
protein
antibodi
induc
natur
infect
vaccin
induc
neutral
antibodi
respons
chloroquin
analogu
shown
inhibit
viru
replic
invitro
whether
chloroquin
hydroxychloroquin
meaning
effect
replic
patient
remain
understood
subject
clinic
trial
postexposur
prophylaxi
treatment
tabl
hydroxychloroquin
approv
fda
emerg
use
hospit
patient
elig
clinic
trial
april
base
limit
clinic
data
concern
rais
toxic
risk
sudden
death
find
ehr
analysi
progress
aid
human
pathophysiolog
enabl
summari
experiment
therapi
investig
figur
tabl
earliest
phase
intervent
attempt
inhibit
entryrepl
modul
critic
host
target
eg
renin
angiotensin
aldosteron
systemraa
inhibitor
analog
serin
proteas
inhibitor
directli
inhibit
function
viral
protein
eg
viral
rnadepend
rna
polymeras
inhibitor
proteas
inhibitor
convalesc
plasma
synthet
immunoglobulin
box
tabl
patient
advanc
stage
diseas
progress
suffer
respiratori
abnorm
therapeut
advanc
target
inflammatori
respons
lead
acut
respiratori
diseas
syndrom
ard
associ
high
mortal
box
includ
antigmcsf
agent
agent
jak
inhibitor
complement
inhibitor
anoth
emerg
option
patient
stage
convalesc
plasma
shown
clinic
benefit
case
relat
viral
diseas
mer
variou
stage
sever
box
administr
convalesc
plasma
contain
activ
specif
antivir
antibodi
may
prevent
attenu
progress
sever
diseas
expand
access
convalesc
plasma
treatment
patient
approv
fda
emerg
ind
use
avail
nationwid
program
led
mayo
clinic
box
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
becom
symptomat
imper
diagnost
test
done
dedic
test
site
avail
confirm
diagnosi
figur
meanwhil
patient
recommend
selfquarantin
home
use
mask
protect
social
distanc
obtain
continu
support
measur
patient
mild
symptom
measur
may
suffici
given
selflimit
natur
viral
syndrom
event
symptom
exacerb
often
mark
worsen
respiratori
distress
medic
evalu
warrant
possibl
hospit
mainstay
treatment
remain
support
care
need
supplement
oxygen
experiment
therapi
intend
block
viral
entri
inhibit
step
viral
life
cycl
necessari
viral
replic
propos
earli
stage
figur
goal
therapi
reduc
viral
load
thu
reduc
chanc
overwhelm
immun
reaction
delay
progress
diseas
among
propos
treatment
option
corticosteroid
avoid
outsid
clinic
trial
suggest
idsa
clinic
evid
establish
conflict
evid
guidanc
steroid
use
steroid
play
role
control
inflamm
collect
clinic
evid
steroid
use
coronaviru
outbreak
suggest
use
corticosteroid
might
exacerb
lung
injuri
patient
progress
sever
critic
diseas
primari
object
manag
provid
respiratori
support
control
immun
overactiv
figur
figur
patient
whose
condit
deterior
critic
statu
primarili
decompens
respiratori
standpoint
may
also
develop
multiorgan
failur
respiratori
failur
cardiac
failur
renal
failur
hypercoagul
state
thrombot
microangiopathi
well
sever
inflammatori
respons
similar
cytokin
releas
syndrom
eventu
reactiv
hemophagocyt
lymphohistiocytosi
syndrom
major
manifest
respiratori
decompens
cytokin
releas
syndrom
acut
respiratori
distress
syndrom
ard
critic
care
support
mechan
support
noninvas
invas
mechan
ventil
instanc
extracorpor
support
vasopressor
renal
replac
therapi
anticoagul
paramount
surviv
critic
ill
patient
per
scc
guidelin
sccmesicm
hand
drug
immunomodulatori
agent
often
use
treat
cytokin
releas
syndrom
may
allow
degre
improv
recoveri
either
lead
sever
critic
diseas
figur
studi
demonstr
highli
unstructur
institut
knowledg
synthes
use
deep
learn
neural
network
expand
beyond
one
institut
diagnost
test
clinic
care
ehr
databas
academ
medic
center
health
system
provid
comprehens
view
clinic
phenotyp
enrich
covidpo
covidneg
patient
day
preced
confirm
diagnost
test
requir
leverag
privacypreserv
feder
softwar
architectur
enabl
medic
center
retain
span
control
deidentifi
ehr
databas
enabl
machin
learn
model
partner
deploy
secur
cloud
infrastructur
seamless
multiinstitut
collabor
augment
intellig
platform
put
patient
privaci
hipaacompli
first
advanc
activ
mayo
clinic
clinic
data
analyt
platform
initi
cdap
capabl
demonstr
studi
rapidli
synthes
million
unstructur
clinic
note
develop
ehrpow
clinic
diagnosi
framework
strengthen
univers
biomed
research
platform
caveat
reli
sole
ehr
infer
mild
phenotyp
may
lead
present
clinic
care
anosmia
may
go
unreport
otherwis
asymptomat
patient
athom
serologybas
test
high
sensit
specif
approv
captur
symptom
becom
increasingli
import
order
facilit
continu
develop
refin
diseas
model
ehrintegr
digit
health
tool
may
help
address
need
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
continu
understand
divers
patient
outcom
holist
infer
ehr
system
equal
import
invest
uncov
molecular
mechan
gain
cellulartissuescal
patholog
insight
largescal
patientderiv
biobank
multiom
sequenc
anecdot
singl
cell
rnaseq
scrnaseq
base
coexpress
analysi
normal
human
sampl
conduct
highlight
rich
heterogen
cell
type
constitut
variou
host
tissu
investig
great
detail
scrnaseq
correl
pattern
molecular
express
scrnaseq
ehrderiv
phenotyp
signal
diseas
progress
largescal
biobank
system
creat
system
enabl
deep
molecular
insight
glean
triangul
tropism
patient
outcom
ultim
connect
dot
tempor
dynam
covidpo
covidneg
clinic
phenotyp
across
divers
patient
popul
multiom
signal
patientderiv
biospecimen
help
advanc
holist
understand
pathophysiolog
set
stage
precis
medicin
approach
diagnost
therapeut
manag
patient
angiotensin
aldosteron
system
raa
inhibitor
recombin
tabl
primari
host
receptor
serin
proteas
implic
spike
protein
prime
viral
bind
recombin
propos
earli
therapi
base
invitro
data
time
effect
raa
inhibitor
uncertain
context
studi
investig
ace
express
modul
coronaviru
infect
relat
lung
injuri
trial
ongo
angiotensin
receptor
blocker
arb
treatment
diminish
downstream
harm
effect
angiotensin
receptor
activ
figur
given
involv
viral
entri
figur
serin
proteas
inhibitor
camostat
evalu
trial
also
consid
earli
stage
infect
remedesivir
nucleosid
analog
attract
much
attent
invivo
inhibit
recent
observ
studi
patient
receiv
remdesivir
compassion
use
found
patient
demonstr
improv
respiratori
statu
day
regimen
anoth
nucleosid
analog
galidesivir
also
evalu
patient
yet
anoth
viral
replic
inhibitor
clinic
trial
favipiravir
figur
favipiravir
broad
spectrum
viral
rna
depend
rna
polymeras
inhibitor
shown
invivo
activ
wide
rang
rna
virus
one
rct
patient
favipiravir
found
improv
clinic
recoveri
rate
rel
umifenovir
viral
entri
inhibitor
tabl
class
medic
wide
propos
use
offlabel
base
postul
hiv
hcv
proteas
share
structur
similar
lopinavirritonavir
combin
shown
promis
found
nonsignific
benefit
random
clinic
trial
rct
patient
china
darunavir
shown
signific
activ
invitro
tabl
multipl
random
control
clinic
trial
underway
usa
determin
efficaci
drug
treatment
antivir
agent
anoth
emerg
option
patient
stage
convalesc
plasma
figur
shown
clinic
benefit
case
relat
viral
diseas
mer
variou
stage
sever
administr
convalesc
plasma
contain
specif
antivir
antibodi
may
prevent
attenu
progress
sever
diseas
expand
access
convalesc
plasma
treatment
patient
avail
program
led
mayo
clinic
synthet
hyperimmun
globulin
also
develop
evalu
antigmcsf
agent
xenograft
studi
found
granulocyt
monocyt
coloni
stimul
factor
gmcsf
neutral
lenzilumab
significantli
reduc
product
inflammatori
cytokin
offer
evid
efficaci
antigmcsf
agent
prevent
cartinduc
cytokin
releas
syndrom
cr
lenzilumab
approv
fda
emerg
ind
use
cr
other
mavrilimumab
gimsilumab
aim
control
undesir
inflamm
myeloid
activ
evalu
clinic
trial
agent
proinflammatori
cytokin
regard
driver
cr
figur
recent
report
suggest
biomark
respiratori
failur
agent
includ
tocilizumab
sarilumab
siltuximab
evalu
random
trial
tabl
use
offlabel
sever
patient
tocilizumab
approv
treatment
cr
observ
studi
patient
sever
pneumonia
treat
tocilizumab
show
promis
result
number
immunomodulatori
agent
link
cr
also
trial
figur
janu
kinas
jak
inhibitor
baricitinib
fedratinib
ruxolitinib
indic
rheumatoid
arthriti
myelofibrosi
test
xenograft
model
chimer
antigen
receptor
car
tcell
therapi
induc
cr
ruxolitinib
avail
expand
access
program
usa
sever
ill
patient
tabl
trial
underway
countri
recent
studi
found
also
bind
key
driver
complement
activ
pathway
lead
complement
hyperactiv
patient
inhibitor
termin
complement
pathway
eculizumab
tri
individu
improv
observ
administr
china
vasodil
recent
report
base
case
itali
germani
note
contrari
establish
understand
ard
patient
ard
retain
rel
high
lung
complianc
demonstr
ventilationperfus
defect
like
aris
perfus
dysregul
hypox
vasoconstrict
therefor
patient
ard
may
benefit
vasodil
address
pathophysiolog
mechan
trial
underway
china
use
inhal
nitric
oxid
patient
mechan
ventil
tabl
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
nferx
augment
curat
technolog
leverag
rapidli
curat
chart
patient
first
read
chart
patient
identifi
group
symptom
set
synonym
word
phrase
exampl
sob
short
breath
dyspnea
among
other
group
short
breath
diseas
medic
patient
identifi
total
symptom
categori
tabl
synonym
synonym
phrase
togeth
synonym
synonym
phrase
captur
multitud
way
symptom
relat
describ
mayo
clinic
electron
health
record
ehr
databas
next
chart
yet
manual
curat
use
stateoftheart
bertbas
neural
network
classifi
symptom
present
present
base
surround
phraseolog
neural
network
use
perform
classif
train
use
nearli
differ
phenotyp
sentenc
achiev
recal
positiveneg
sentiment
classif
went
individu
sentenc
either
accept
sentenc
reject
reclassifi
neural
network
activ
retrain
curat
progress
lead
stepwis
increas
curat
effici
model
accuraci
step
process
label
sentenc
label
either
present
present
model
train
data
set
trainingtest
split
achiev
score
present
present
classif
respect
model
appli
addit
sentenc
step
rapidli
correct
human
classif
error
retrain
gener
newer
version
model
step
iter
step
addit
sentenc
model
achiev
score
step
step
classif
presentnot
present
due
augment
natur
approach
step
requir
success
less
input
human
annot
model
appli
clinic
note
covidpo
patient
million
clinic
note
covidneg
patient
first
differ
date
particular
note
written
pcr
test
date
patient
correspond
note
form
rel
date
measur
note
pcr
test
date
treat
day
note
preced
assign
bertbas
neural
network
appli
note
provid
set
symptom
present
point
time
patient
question
map
invert
determin
symptom
rel
date
set
uniqu
patient
experienc
symptom
synonym
group
symptom
comput
count
proport
covidpo
covidneg
patient
deem
symptom
least
one
note
day
prior
pcr
test
addit
comput
ratio
proport
indic
extent
preval
symptom
covidpo
cohort
compar
covidneg
cohort
standard
z
hypothesi
test
perform
pvalu
report
symptom
captur
tempor
evolut
symptom
covidpo
covidneg
cohort
process
describ
repeat
consid
count
proport
day
independ
pairwis
analysi
phenotyp
perform
consid
phenotyp
pair
origin
set
individu
phenotyp
pair
calcul
number
patient
covidpo
covidneg
cohort
wherein
phenotyp
occur
least
week
preced
pcr
test
patient
proport
z
test
pvalu
comput
benjaminihochberg
correct
appli
account
multipl
hypothesi
test
research
conduct
irb
studi
patient
characterist
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
augment
curat
electron
health
record
ehr
inform
strateg
oper
decis
analysi
ehr
perform
privacypreserv
environ
secur
control
mayo
clinic
nferenc
mayo
clinic
subscrib
basic
ethic
principl
underli
conduct
research
involv
human
subject
set
forth
belmont
report
strictli
ensur
complianc
common
rule
code
feder
regul
cfr
protect
human
subject
sinc
success
entri
viru
cell
requir
prime
cellular
host
proteas
hypothes
cell
express
cell
could
harbor
cours
infect
thu
probe
express
singlecel
studi
human
tissu
avail
nferx
singl
cell
platform
http
academianferxcom
tissu
profil
ensur
minimum
cell
cell
popul
minimum
cell
cell
popul
coexpress
nonzero
express
express
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
tabl
key
covidpo
amplifi
phenotyp
week
preced
pcr
test
ie
day
day
highlight
gray
ratio
covidpo
covidneg
proport
repres
fold
chang
amplif
phenotyp
covidpo
patient
set
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
tabl
tempor
analysi
ehr
clinic
note
week
preced
pcr
test
ie
day
day
day
pcr
test
day
subsequ
pair
day
day
day
covidpo
covidneg
patient
tempor
enrich
symptom
quantifi
use
ratio
covidpo
patient
proport
covidneg
patient
proport
day
patient
proport
row
label
posit
n
neg
n
repres
percentag
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
supplementari
materi
figur
celltyp
connect
pathophysiolog
infer
high
express
human
scrna
seq
dataset
scatter
plot
depict
express
infer
singlecel
rnaseq
profil
human
tissu
use
nferx
singl
cell
platform
xaxi
repres
mean
ln
express
cell
yaxi
repres
mean
ln
express
correspond
celltyp
respect
tissu
color
scatter
plot
depict
tissu
origin
size
point
scatter
plot
repres
percentag
singl
cell
celltyp
coexpress
nonzero
express
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
figur
diseas
progress
divid
multipl
stage
appropri
therapeut
chosen
base
specif
pathophysiolog
mechan
use
nferx
knowledg
synthesi
associ
molecular
marker
step
diseas
progress
also
identifi
see
supplementari
method
detail
nferx
knowledg
synthesi
order
captur
biomed
literatur
base
associ
nferx
platform
defin
two
score
local
score
global
score
describ
previous
park
j
et
al
recapitul
retrospect
predict
biomed
associ
use
temporallyen
word
embed
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
schemat
deriv
nferx
local
global
score
quantifi
associ
concept
across
literatur
b
heatmap
nferx
local
score
captur
associ
discuss
literatur
select
treatment
drug
relat
phenotyp
order
captur
biomed
literatur
base
associ
nferx
platform
defin
two
score
local
score
global
score
describ
previous
park
j
et
al
recapitul
retrospect
predict
biomed
associ
use
temporallyen
word
embed
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
tabl
collect
treatment
undergo
clinic
trial
inhibit
viral
entri
downstream
activ
angiotensin
mediat
inflamm
effect
ace
inhibit
evalu
inhibit
angiotensin
receptor
given
use
viral
entri
arb
evalu
potenti
efficaci
andor
risk
covid
tocilizumab
inhibitor
propos
reduc
risk
cytokin
releas
syndrom
covid
siltuximab
inhibitor
propos
reduc
risk
cytokin
releas
syndrom
covid
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
select
capn
inhibitor
initi
develop
pulmonari
fibrosi
studi
found
capn
inhibit
led
reduc
replic
bevacizumab
antivegf
antibodi
propos
attenu
increas
vascular
permeabl
covidinduc
vascular
inflamm
increas
secret
mucu
compon
respiratori
tract
allevi
respiratori
inflamm
initi
develop
gvhd
shown
reduc
inflamm
bind
damp
siglec
modul
immun
respons
evalu
china
efficaci
upper
respiratori
tract
diseas
nintedanib
tyrosin
kinas
inhibitor
initi
develop
idiopath
pulmonari
fibrosi
like
approv
antiinflammatori
antifibrot
activ
tlr
agonist
propos
prevent
covid
oligonucleotid
initi
approv
hepat
venoocclus
diseas
like
propos
effect
modul
endotheli
injuri
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
ccbyncnd
intern
licens
made
avail
authorfund
grant
medrxiv
licens
display
preprint
perpetu
certifi
peer
review
copyright
holder
preprint
version
post
april
http
doi
medrxiv
preprint
